Addex Reports 2019 Full Year Audited Results and Provides Corporate Update
April 08, 2020 01:00 ET
|
Addex Therapeutics
Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD programAdditional funding of...
Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020
April 06, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 6, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results
March 18, 2020 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 18, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020
March 13, 2020 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 13, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board
March 03, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 3, 2020 - Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
February 26, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, February 26, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics to Ring the Nasdaq Stock Market Closing Bell
February 03, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland and New York, February 3, 2020 - Addex Therapeutics Ltd (Nasdaq & SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Starts Trading American Depositary Shares on Nasdaq Under Ticker ADXN
January 29, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 29, 2020 -- Addex Therapeutics Ltd (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Provides Trading Update and Completes 2019 with Cash Position of CHF31.5 million
January 13, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 13, 2020 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that it completed 2019 with...
Addex to Attend 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, January 8, 2020 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today announced that members of its management...